Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with α-synuclein at the single molecule level

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Nübling, Georg ^a,b   Bader, Benedikt ^a,b   Levin, Johannes ^a,b   Hildebrandt, Jenna ^a   Kretzschmar, Hans ^a   Giese, Armin ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Synuclein; Aluminium; Alzheimers disease; GSK 3 beta; Iron; Metal ion; Oligomer; Parkinsons disease; Phosphorylation; Tau

Indexed keywords

ALPHA SYNUCLEIN; ALUMINUM; DIMETHYL SULFOXIDE; GLYCOGEN SYNTHASE KINASE 3BETA; IRON; METAL ION; OLIGOMER; TAU PROTEIN;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ELECTROPHORESIS; FLUORESCENCE ANALYSIS; OLIGOMERIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SCANNING INTENSELY FLUORESCENT TARGET; WESTERN BLOTTING;

ALPHA-SYNUCLEIN; CELL LINE, TUMOR; ESCHERICHIA COLI; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IRON; METALS; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; SOLVENTS; TAU PROTEINS;

EID: 84867519558     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-35     Document Type: Article

References (61)

1. Brain levels of microtubule-associated protein tau are elevated in Alzheimers disease: a radioimmuno-slot-blot assay for nanograms of the protein. Khatoon S, Grundke-Iqbal I, Iqbal K, J Neurochem 1992 59 750 753 10.1111/j.1471-4159.1992.tb09432.x 1629745
2. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I, J Biol Chem 1993 268 24374 24384 8226987
3. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Goedert M, Jakes R, Vanmechelen E, Neurosci Lett 1995 189 167 169 10.1016/0304-3940(95)11484-E 7624036
4. AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimers disease. Buee-Scherrer V, Condamines O, Mourton-Gilles C, Jakes R, Goedert M, Pau B, Delacourte A, Brain Res Mol Brain Res 1996 39 79 88 8804716
5. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimers disease. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H, Brain 2006 129 3035 3041 10.1093/brain/awl269 17012293
6. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, et al. Arch Gen Psychiatry 2004 61 95 102 10.1001/archpsyc.61.1.95 14706948
7. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH, J Neurochem 2000 74 1587 1595 10737616
8. Alzheimers disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, Hanger D, Mulot S, Marquardt B, Stabel S, et al. Curr Biol 1994 4 1077 1086 10.1016/S0960-9822(00)00246-3 7704571
9. Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture. Li X, Lu F, Tian Q, Yang Y, Wang Q, Wang JZ, J Neural Transm 2006 113 93 102 10.1007/s00702-005- 0303-7 15959856
10. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. Spittaels K, Van den Haute C, Van Dorpe J, Geerts H, Mercken M, Bruynseels K, Lasrado R, Vandezande K, Laenen I, Boon T, et al. J Biol Chem 2000 275 41340 41349 10.1074/jbc.M006219200 11007782
11. Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta transgenes. Brownlees J, Irving NG, Brion JP, Gibb BJ, Wagner U, Woodgett J, Miller CC, Neuroreport 1997 8 3251 3255 10.1097/00001756-199710200- 00013 9351652
12. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I, J Neuropathol Exp Neurol 1997 56 70 78 10.1097/00005072- 199701000-00007 8990130
13. Increased level of active GSK-3beta in Alzheimers disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Leroy K, Yilmaz Z, Brion JP, Neuropathol Appl Neurobiol 2007 33 43 55 17239007
14. Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation. Baum L, Hansen L, Masliah E, Saitoh T, Mol Chem Neuropathol 1996 29 253 261 10.1007/BF02815006 8971700
15. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K, Acta Neuropathol 1996 92 232 241 10.1007/s004010050513 8870824
16. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF, J Neuropathol Exp Neurol 1999 58 1010 1019 10.1097/00005072-199909000-00011 10499443
17. Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. Rankin CA, Sun Q, Gamblin TC, Mol Neurodegener 2007 2 12 10.1186/1750-1326-2-12 17598919
18. Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Liu F, Li B, Tung EJ, Grundke-Iqbal I, Iqbal K, Gong CX, Eur J Neurosci 2007 26 3429 3436 10.1111/j.1460-9568.2007.05955.x 18052981
19. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Wang JZ, Grundke-Iqbal I, Iqbal K, Eur J Neurosci 2007 25 59 68 10.1111/j.1460-9568.2006.05226.x 17241267
20. GSK-3beta phosphorylation of functionally distinct tau isoforms has differential, but mild effects. Voss K, Gamblin TC, Mol Neurodegener 2009 4 18 10.1186/1750-1326-4-18 19409104
21. Identification and isolation of a hyperphosphorylated, conformationally changed intermediate of human protein tau expressed in yeast. Vandebroek T, Vanhelmont T, Terwel D, Borghgraef P, Lemaire K, Snauwaert J, Wera S, Van Leuven F, Winderickx J, Biochemistry 2005 44 11466 11475 10.1021/bi0506775 16114883
22. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, Geschwind DH, Neuron 2002 34 509 519 10.1016/S0896-6273(02)00706-7 12062036
23. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F, J Neurochem 2006 99 1445 1455 10.1111/j.1471-4159.2006.04139.x 17059563
24. Phosphorylation sensitizes microtubule-associated protein tau to Al(3+)-induced aggregation. Li W, Ma KK, Sun W, Paudel HK, Neurochem Res 1998 23 1467 1476 10.1007/BF03181171 9821149
25. Pseudophosphorylation of tau protein alters its ability for self-aggregation. Haase C, Stieler JT, Arendt T, Holzer M, J Neurochem 2004 88 1509 1520 10.1046/j.1471-4159.2003.02287.x 15009652
26. Aluminum modifies the properties of Alzheimers disease PHF tau proteins in vivo and in vitro. Shin RW, Lee VM, Trojanowski JQ, J Neurosci 1994 14 7221 7233 7525898
27. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimers disease. Yamamoto A, Shin RW, Hasegawa K, Naiki H, Sato H, Yoshimasu F, Kitamoto T, J Neurochem 2002 82 1137 1147 12358761
28. Experimental Production of Neurofibrillary Degeneration. I. Light Microscopic Observations. Klatzo I, Wisniewski H, Streicher E, J Neuropathol Exp Neurol 1965 24 187 199 10.1097/00005072-196504000-00002 14280496
29. Brain aluminum in Alzheimers disease using an improved GFAAS method. Xu N, Majidi V, Markesbery WR, Ehmann WD, Neurotoxicology 1992 13 735 743 1302300
30. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimers disease: a laser microprobe (LAMMA) study. Good PF, Perl DP, Bierer LM, Schmeidler J, Ann Neurol 1992 31 286 292 10.1002/ana.410310310 1637136
31. Aluminum in hippocampal neurons from humans with Alzheimers disease. Walton JR, Neurotoxicology 2006 27 385 394 10.1016/j.neuro.2005.11.007 16458972
32. Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. Krewski D, Yokel RA, Nieboer E, Borchelt D, Cohen J, Harry J, Kacew S, Lindsay J, Mahfouz AM, Rondeau V, J Toxicol Environ Health B Crit Rev 2007 10 Suppl 1 1 269 18085482
33. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Smith MA, Harris PL, Sayre LM, Perry G, Proc Natl Acad Sci U S A 1997 94 9866 9868 10.1073/pnas.94.18.9866 9275217
34. Non-haem iron histochemistry of the normal and Alzheimers disease hippocampus. Morris CM, Kerwin JM, Edwardson JA, Neurodegeneration 1994 3 267 275 7842297
35. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimers disease: possible relation to oxidative stress. Deibel MA, Ehmann WD, Markesbery WR, J Neurol Sci 1996 143 137 142 10.1016/S0022-510X(96)00203-1 8981312
36. Generation of ferric iron links oxidative stress to -synuclein oligomer formation. Levin J, Högen T, Hillmer A, Bader B, Schmidt F, Kretzschmar H, Bötzel K, Giese A, J Parkinsons Dis 2011 1 205 216 23060010
37. Converse modulation of toxic alpha-synuclein oligomers in living cells by N-benzylidene-benzohydrazide derivates and ferric iron. Hillmer AS, Putcha P, Levin J, Hogen T, Hyman BT, Kretzschmar H, McLean PJ, Giese A, Biochem Biophys Res Commun 2010 391 461 466 10.1016/j.bbrc.2009.11.080 19914207
38. Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. Kostka M, Hogen T, Danzer KM, Levin J, Habeck M, Wirth A, Wagner R, Glabe CG, Finger S, Heinzelmann U, et al. J Biol Chem 2008 283 10992 11003 10.1074/jbc.M709634200 18258594
39. C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Masliah E, Acta Neuropathol 2000 99 296 304 10.1007/PL00007441 10663973
40. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW, J Neuropathol Exp Neurol 2003 62 389 397 12722831
41. Initiation and synergistic fibrillization of tau and alpha-synuclein. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM, Science 2003 300 636 640 10.1126/science.1082324 12714745
42. Preparation and characterization of neurotoxic tau oligomers. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R, Biochemistry 2010 49 10039 10041 10.1021/bi1016233 21047142
43. Granular tau oligomers as intermediates of tau filaments. Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, Miyasaka T, Murayama S, Ikai A, Takashima A, Biochemistry 2007 46 3856 3861 10.1021/bi061359o 17338548
44. Tau suppression in a neurodegenerative mouse model improves memory function. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, et al. Science 2005 309 476 481 10.1126/science.1113694 16020737
45. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB, Science 2001 293 711 714 10.1126/science.1062382 11408621
46. Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. Kimura T, Fukuda T, Sahara N, Yamashita S, Murayama M, Mizoroki T, Yoshiike Y, Lee B, Sotiropoulos I, Maeda S, Takashima A, J Biol Chem 2010 285 38692 38699 10.1074/jbc.M110.136630 20921222
47. Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets. Bieschke J, Giese A, Schulz-Schaeffer W, Zerr I, Poser S, Eigen M, Kretzschmar H, Proc Natl Acad Sci U S A 2000 97 5468 5473 10.1073/pnas.97.10.5468 10805803
48. Single particle detection and characterization of synuclein co-aggregation. Giese A, Bader B, Bieschke J, Schaffar G, Odoy S, Kahle PJ, Haass C, Kretzschmar H, Biochem Biophys Res Commun 2005 333 1202 1210 10.1016/j.bbrc.2005.06.025 15978545
49. Single particle analysis of tau oligomer formation induced by metal ions and organic solvents. Bader B, Nubling G, Mehle A, Nobile S, Kretzschmar H, Giese A, Biochem Biophys Res Commun 2011 411 190 196 10.1016/j.bbrc.2011.06.135 21726531
50. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM, Biochemistry 1999 38 3549 3558 10.1021/bi981874p 10090741
51. Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization. Sun Q, Gamblin TC, Biochemistry 2009 48 6002 6011 10.1021/bi900602h 19459590
52. Assembly of Alzheimer-like filaments from full-length tau protein. Crowther RA, Olesen OF, Smith MJ, Jakes R, Goedert M, FEBS Lett 1994 337 135 138 10.1016/0014-5793(94)80260-2 8287967
53. Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. Perez M, Valpuesta JM, Medina M, Montejo de Garcini E, Avila J, J Neurochem 1996 67 1183 1190 8752125
54. Brain aluminum, magnesium and phosphorus contents of control and Alzheimer-diseased patients. Andrasi E, Pali N, Molnar Z, Kosel S, J Alzheimers Dis 2005 7 273 284 16131728
55. Ca2+ and Mg2+ selectively induce aggregates of PHF-tau but not normal human tau. Yang LS, Ksiezak-Reding H, J Neurosci Res 1999 55 36 43 10.1002/(SICI)1097-4547(19990101)55:1<36::AID-JNR5>3.0.CO;2-E 9890432
56. Fibrillization of alpha-synuclein and tau in familial Parkinsons disease caused by the A53T alpha-synuclein mutation. Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, Lee VM, Exp Neurol 2004 187 279 288 10.1016/j.expneurol.2004.01.007 15144854
57. Induction of Intracellular Tau Aggregation Is Promoted by a-Synuclein Seeds and Provides Novel Insights into the Hyperphosphorylation of Tau. Waxman EA, Giasson BI, J Neurosci 2011 31 7604 7618 10.1523/JNEUROSCI.0297-11.2011 21613474
58. E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. Emmer KL, Waxman EA, Covy JP, Giasson BI, J Biol Chem 2011 286 35104 35118 10.1074/jbc.M111.247965 21846727
59. Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Ksiezak-Reding H, Liu WK, Yen SH, Brain Res 1992 597 209 219 10.1016/0006-8993(92)91476-U 1472994
60. Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. Arai T, Guo JP, McGeer PL, J Biol Chem 2005 280 5145 5153 15542598
61. Increased alpha-synuclein aggregation following limited cleavage by certain matrix metalloproteinases. Levin J, Giese A, Boetzel K, Israel L, Hogen T, Nubling G, Kretzschmar H, Lorenzl S, Exp Neurol 2009 215 201 208 10.1016/j.expneurol.2008.10.010 19022250